Antibody Tx reduces graft-vs-host post stem cell transplant

Antibody tx reduces graft-vs-host post stem cell transplant

(HealthDay)—Antibody therapy before stem cell transplant may benefit patients with acute leukemia, according to research published in the Jan. 7 issue of the New England Journal of Medicine.

The study included 168 leukemia patients treated at 27 different centers. The volunteers were randomly assigned to receive antihuman T-lymphocyte immune globulin (ATG) or not. After an average follow-up of two years, 32.2 percent of the patients given ATG had chronic graft-versus-host disease. But, 68.7 percent of patients who weren't given ATG had chronic graft-versus-host disease.

At two years, the survival rate was similar in patients who received ATG or didn't. But, the rate of survival in which they were free from chronic graft-versus-host disease and was significantly better among patients given the antibody—36.6 versus 16.8 percent, the researchers found.

"Graft-versus-host disease is the most serious complication after stem cell transplantation," lead researcher Francesca Bonifazi, M.D., from the Institute of Hematology at Bologna University in Italy, told HealthDay. "Using [ATG] reduces the risk of complications of without increasing the risk of leukemia recurrence and infections."


Explore further

Depletion of naive T cells from stem cell grafts limits chronic graft-versus host disease

More information: Full Text
Journal information: New England Journal of Medicine

Copyright © 2016 HealthDay. All rights reserved.

Citation: Antibody Tx reduces graft-vs-host post stem cell transplant (2016, January 7) retrieved 15 November 2019 from https://medicalxpress.com/news/2016-01-antibody-tx-graft-vs-host-stem-cell.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments